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Abstract
Background: Vascular disease is a feature of aging, and coronary vascular events are a major
source of morbidity and mortality in rare premature aging syndromes. One such syndrome is
caused by mutations in the lamin A/C (LMNA) gene, which also has been implicated in familial insulin
resistance. A second gene related to premature aging in man and in murine models is the KLOTHO
gene, a hypomorphic variant of which (KL-VS) is significantly more common in the first-degree
relatives of patients with premature coronary artery disease (CAD). We evaluated whether
common variants at the LMNA or KLOTHO genes are associated with rigorously defined premature
CAD.
Methods:  We identified 295 patients presenting with premature acute coronary syndromes
confirmed by angiography. A control group of 145 patients with no evidence of CAD was recruited
from outpatient referral clinics. Comprehensive haplotyping of the entire LMNA gene, including the
promoter and untranslated regions, was performed using a combination of TaqMan® probes and
direct sequencing of 14 haplotype-tagging single nucleotide polymorphisms (SNPs). The KL-VS
variant of the KLOTHO gene was typed using restriction digest of a PCR amplicon.
Results: Two SNPs that were not in Hardy Weinberg equilibrium were excluded from analysis.
We observed no significant differences in allele, genotype or haplotype frequencies at the LMNA or
KLOTHO loci between the two groups. In addition, there was no evidence of excess homozygosity
at the LMNA locus.
Conclusion: Our data do not support the hypothesis that premature CAD is associated with
common variants in the progeroid syndrome genes LMNA and KLOTHO.
Background
CAD is the most common cause of death in the developed
world and an increasingly important cause of mortality in
the developing world. The dominant pathophysiologic
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paradigm in CAD is that observed in a relatively rare
inherited form of atherosclerosis; Familial Hypercholeste-
rolemia caused by mutations in the LDL receptor[1]. In
this condition a primary endocytic abnormality leads, at
least partly though excess elevations in LDL cholesterol, to
focal endothelial injury, and chronic inflammatory
lesions of the arterial wall. Ultimately through plaque
rupture and thrombosis there is episodic end-artery occlu-
sion. Importantly, while the later phases of this process
appear to be relevant to many forms of CAD, the earliest
injury is unknown in most forms of vascular disease pre-
cluding truly preventative strategies. Recently the identifi-
cation of Mendelian forms of coronary disease has
suggested that other major pathways may contribute to
each stage of the process[2,3]. Family history is a major
risk factor for premature CAD, but the genetic contribu-
tions to common forms of the disease are unknown[4].
The high prevalence of CAD in older age groups suggests
that some forms of atherosclerosis are an integral part of
the aging process, and inherited premature aging (or pro-
geroid) syndromes are associated with extensive vascular
disease[5]. The causal genes underlying two such rare
Mendelian forms of aging recently have been identified.
Discrete mutations in the LMNA gene have been demon-
strated to cause a range of inherited syndromes including
a variant of Emery-Dreifus muscular dystrophy, dilated
cardiomyopathy with conduction disease and Charcot-
Marie-Tooth disease[6]. The mechanisms of this remarka-
ble pleiotropy are unknown, but have been attributed to
discrete functions of different lamin domains in individ-
ual tissues. At least two of the syndromes caused by lamin
mutations include premature CAD. Some lamin muta-
tions result in Dunnigan's partial lipodystrophy in which
CAD is a prominent feature, especially in females. These
individuals suffer from an unusual form of insulin resist-
ance, with morphologic abnormalities including hemifa-
cial loss of subcutaneous adipose tissue, as well as
hypertension, dyslipidemia and vascular disease. Patients
in such families also have elevated CRP levels, and lower
leptin and adiponectin levels[7]. A second aging disorder,
Hutchison-Gilford Progeria Syndrome (HGPS), is the
result of recurrent de novo mutations of a single nucleotide
in exon 11 of the LMNA gene have been shown to cause
the progeroid disorder)[8,9]. HGPS is characterized by
extreme 'aging' in multiple tissues with most affected indi-
viduals dying from atherosclerotic vascular disease in
their late teens. In many cases of HGPS there also
appeared to be germ-line loss of the second LMNA allele,
suggesting that somatic mutations at this locus might lead
to more common forms of aging, possibly in a tissue-
restricted manner. Given the extreme forms of vascular
disease seen in these two laminopathies, and the strong
association of the metabolic syndrome with CAD we
explored the role of LMNA variation in premature coro-
nary disease.
The second gene implicated in progeria is KLOTHO
encoding a membrane protein of unknown function shar-
ing homology with beta-glucosidases. Targeted deletion
of the Klotho locus in mice results in reduced longevity,
vascular disease, osteoporosis and chronic lung dis-
ease[10]. Recent work has demonstrated impaired angio-
genesis and vasculogenesis in these Klotho-deficient
mice[11]. A role for the ortholog of Klotho in human aging
was suggested by the finding that a specific KLOTHO
allele (KL-VS) which changes amino-acid sense is under-
represented in older age groups. This finding was repro-
duced in three ethnically distinct groups[12]. Individuals
homozygous for the KL-VS allele were 2.6-fold less likely
to survive to 65 years of age or greater. A role for the
human KLOTHO gene in vascular disease also has been
suggested by work demonstrating that the same KL-VS
allele is associated with increased risk of occult atheroscle-
rosis in a high-risk sample consisting of siblings of indi-
viduals with premature CAD. This effect of the KL-VS
allele was evident even after adjustment for known risk
factors [13]. We also explored the role of the KL-VS allele
in our cohort of subjects with premature CAD.
Previous studies of these two aging genes largely have
been confined to rare kindreds or cohorts with direct evi-
Table 1: Baseline demography of study cohorts. Values are presented as number (percentage) unless otherwise indicated.
Baseline Characteristics PCAD Controls P-value
Number 295 145
Age at enrollment, years 47.4 ± 7.1 54.3 ± 10.8 <0.001
Male gender 199 (68.2) 115 (79.3)
BMI 30.2 ± 6.6 27.1 ± 4.4 <0.001
Cardiovascular risk factors
Diabetes mellitus 55 (18.8) 7 (4.86) <0.001
Hypertension 112 (38.2) 15 (10.4) <0.001
Hypercholesterolemia 104 (35.4) 30 (38.0) 0.67
Statin use 104 (35.4) 30 (38.0) 0.67
Smoking 113 (38.4) 8 (12.5) <0.001BMC Medical Genetics 2005, 6:38 http://www.biomedcentral.com/1471-2350/6/38
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Linkage disequilibrium plot demonstrates the inheritance of tagged SNPs as a single block within the LMNA gene Figure 1
Linkage disequilibrium plot demonstrates the inheritance of tagged SNPs as a single block within the LMNA gene.BMC Medical Genetics 2005, 6:38 http://www.biomedcentral.com/1471-2350/6/38
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dence of CAD. We tested the hypothesis that common var-
iants at the LMNA and KLOTHO loci were associated with
angiographically-defined premature CAD in a case-con-
trol association study.
Methods
Subjects
Between 1999 to 2003, we attempted to recruit serial
patients with premature CAD presenting to the Massachu-
setts General Hospital were recruited. Inclusion criteria
were; documented acute coronary syndrome (myocardial
infarction or unstable angina) confirmed on coronary
angiogram; and age ≤ 50 years for males or ≤ 55 years for
females. Exclusion criteria were: logistic difficulties pre-
cluding enrollment, history of familial dyslipidemia, type
I diabetes, endstage renal disease, a history of recent
trauma, sepsis, or previous thoracic irradiation. All
patients gave written informed consent prior to study
enrollment. A structured interview and physical examina-
tion was performed during the initial hospitalization. This
included a detailed medical history, careful documenta-
tion of cardiovascular risk factors, current and past medi-
cations and a comprehensive family history using an
instrument which we have previously validated. Hyper-
tension was defined as previous antihypertensive use or a
documented untreated systolic blood pressure >140
mmHg or diastolic>90 mmHg. Hypercholesterolemia was
defined as an LDL cholesterol >130 mg/dl. Diabetes mel-
litus was defined as the use of diet, oral hypoglycemic
agents or insulin to control blood glucose. Smoking was
defined as the regular use of tobacco at any stage in the
previous decade. A blood sample for nucleic acid extrac-
tion was obtained at enrollment. In parallel, over the
same time period a control population was recruited from
outpatient referral clinics at Massachusetts General Hospi-
tal. These control subjects were free from symptoms sug-
gestive of CAD or ECG abnormalities, and all had
undergone transthoracic echocardiography to exclude the
presence of subclinical structural heart disease.
Genetic analyses
LMNA genotyping
To generate representative haplotypes at the LMNA locus,
we first assembled in silico 35,374 base pairs of reference
sequence encompassing the entire coding region of the
gene including sequence reported by Lin et al[14], consen-
sus finished sequence and trace data from the region from
the Human Genome Project[15]. Additional direct
sequencing of the relevant genomic regions was per-
formed where necessary. Sequence assembly and analysis
was performed using the aid of Vector NTI version 8
(InforMax™). SNPs spanning the LMNA gene were
selected from dbSNP [16] and the published literature.
Selection was based on genomic coverage and where pos-
sible on polymorphism information content. In addition,
all common (defined as those present in ≥ 5% of the pop-
ulation) SNPs changing amino acid sense were included.
A combination of TaqMan®  based assays and direct
sequencing was used to type the SNPs in an initial subset
of the study cohort. Details of probes and primers are
available in Table 5. Allelic discrimination using TaqMan®
was performed using 5 ng of sample DNA in a 25 µL reac-
tion containing 12.5 µL TaqMan®  Universal PCR Mix
(Applied Biosystems), 300 nM primers, 200 nM TaqMan®
MGB probes (Applied Biosystems). Reaction conditions
consisted of preincubation at 50°C for 2 minutes, 95°C
for 10 minutes, then cycling for 40 cycles of 95°C, 15 sec-
onds; 60°C, 1 minute. Amplifications were performed in
an ABI Prism 7000 machine (Applied Biosystems) for
continuous fluorescence monitoring. Direct cycle
Table 2: Distribution of major haplotype blocks in LMNA among patients with premature CAD and the control population.
Haplotype Frequency
Haplot
ype
i ii iii iv v vi vii viii ix x xi Overal
l
PCAD
*
Contr
ols
p-
value
I C G G A T G C G A C G 0.44 0.43 0.45 0.55
II C G G A T G T G A C G 0.30 0.29 0.29 0.85
III T G G A T G C G A C A 0.13 0.13 0.14 0.82
IV T T A G C A C C G T G 0.05 0.05 0.07 0.25
V T G G A T G C G A C G 0.05 0.05 0.04 0.41
VI T G G G T A C C A T G 0.02 0.02 0.01 0.23
SNP ids; i-rs2485662;ii-rs517606;iii-rs593987;iv-rs528636;v-rs508641;vi-rs553016;vii-rs4641;viii-rs7339;ix-rs568036;x-rs568035;xi-rs6669212.
*PCAD: Group with premature coronary artery disease
2 SNPs (rs3204564 and rs536857) that were not in Hardy Weinberg equilibrium were excluded.BMC Medical Genetics 2005, 6:38 http://www.biomedcentral.com/1471-2350/6/38
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sequencing was used to type one series of closely linked
SNPs as detailed in Table 5.
For each LMNA SNP the allele frequencies were defined
and testing for Hardy Weinberg equilibrium was per-
formed. Haplotypes at the LMNA locus were defined
using the modified estimation-maximization algorithm
implemented in the software package Haploview [17].
Following confirmation that specific SNPs did not segre-
gate independently but were in linkage disequilibrium
with each other, the methods of expectation-maximiza-
tion-based haplotype frequency estimation and permuta-
tion-based hypothesis testing were performed as
previously described [18].
KLOTHO genotyping
The KL-VS allele was typed using modifications of the
published conditions[12]. Sample DNA was amplified by
PCR (sense primer 5'-GCCAAAGTCTGGCATCTCTA-3';
antisense primer 5'-TTCCATGATGAACTTTTTGAGG-3')
under the following conditions: 95°C for 2 minutes, fol-
lowed by 35 cycles of 94°C for 30 seconds, 60°C for 30
seconds, and 72°C for 1 minute, followed by a 20 minute
72°C final extension. PCR products were then digested
with MaeIII (Roche) at 55°C for 16 hours and electropho-
retically separated on a 2% agarose gel. The KL-VS allele is
characterized by diagnostic MaeIII restriction fragments of
265 and 185 bp respectively. Allele frequencies were
determined by gene counting.
Statistical analyses
Continuous variables are presented as means ± SD. Base-
line characteristics were compared using the Student's
unpaired t test for continuous data and the Chi-square or
Fisher's exact test for categorical data. Single-locus tests of
association between either SNP allele frequencies or SNP
genotype frequencies and case-control status were carried
out using standard contingency Chi-square tests. Based on
the method of Chapman and Nam and assuming an allele
frequency of 0.20, our study design has 93% power to
detect a difference in allele frequency of 1.8 times or more
at α = 0.05 [19].
Results
Subjects
During the study period we enrolled 295 subjects with
premature CAD and 145 controls. The premature CAD
cohort, as expected, exhibited a higher proportion with
diabetes mellitus, hypertension, and smoking (see Table
1). In addition, the premature CAD cohort was younger
and more likely to be obese. Self-reported ethnicity was
similar between the two cohorts.
LMNA genotypes
Two SNPs (rs3204564 and rs536857) that were not in
Hardy Weinberg equilibrium were not included in subse-
quent analyses. Median spacing of the SNPs was 1,206 bp
apart with a range of 146 bp to 7,063 bp (SNPs rs568035
and rs568036 are adjacent to each other). Haplotype anal-
ysis revealed the presence of 6 haplotypes, with the most
frequent occuring at an overall frequency of 43.8% (see
Figure 1 and Table 2). Haplotype allele frequencies did
not differ significantly between patients and controls.
Subsequently each individual SNP was tested independ-
ently for association with premature CAD. No significant
difference in allele frequency for any SNP in the LMNA
gene was observed between the control and patient
groups (see Table 3). In analyses adjusting for age, BMI,
gender, hypertension, diabetes mellitus, statin use, and
smoking history we did not observe any significant asso-
ciations.
KLOTHO genotypes
Previous studies have documented the heterozygote car-
rier frequency for the KL-VS allele to be between 20 to
30% and the homozygosity frequency to be between 1 to
Table 3: Frequency of major SNP allele in LMNA among patients with premature CAD and the control population.
SNP Major Allele Freq in PCAD* Freq in Controls Minor Allele p-value
rs955383 A 0.78 0.76 G 0.46
rs2485662 C 0.73 0.74 T 0.75
rs517606 G 0.94 0.93 T 0.55
rs593987 G 0.94 0.93 A 0.62
rs528636 A 0.92 0.92 G 0.92
rs508641 T 0.95 0.93 C 0.35
rs553016 G 0.93 0.92 A 0.89
rs4641 C 0.70 0.71 T 0.81
rs7339 G 0.93 0.92 C 0.90
rs568036 A 0.95 0.93 G 0.35
rs568035 C 0.92 0.92 T 1.00
rs6669212 G 0.86 0.86 A 1.00
* PCAD: Group with premature coronary artery disease
2 SNPs (rs3204564 and rs536857) that were not in Hardy Weinberg equilibrium were excluded.BMC Medical Genetics 2005, 6:38 http://www.biomedcentral.com/1471-2350/6/38
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4% [12]. The allele distribution is very similar in our
patient and control cohorts, and no significant difference
in allele frequencies was observed between these groups
(see Table 4). The frequency of the KL-VS allele was 14.0%
in patients with premature CAD compared to 18.2% in
the control population (p = 0.09).
Discussion
We hypothesized that common variation at the LMNA or
KLOTHO loci might result in typical forms of coronary
disease in the absence of progeroid syndromes. We tested
not only the hypothesis that alleles of LMNA or KLOTHO
would be associated with premature CAD (a population
enriched for inherited contributions), but also pre-speci-
fied that such premature vasculopathy might be associ-
ated with an excess of homozygosity at the LMNA locus.
Our data suggest that, within the constraints of the current
study, there is no association between common variation
in the aging genes LMNA  or  KLOTHO  and rigorously
defined premature CAD. Further, there was no evidence of
excess homozygosity at the LMNA  locus, rendering a
somatic "two-hit" mechanism at this locus less likely as a
potential cause of CAD. These data contradict previous
findings in smaller studies and emphasize the difficulties
intrinsic to such genetic association studies.
Possible explanations for contradictory findings
Genetic association studies relating common or "com-
plex" phenotypes in large patient cohorts may be the only
method capable of unraveling small population-wide
genetic effects, but these studies prove difficult to repro-
duce and are of limited utility in defining causation [20-
24]. Several intrinsic limitations of genetic association
approaches contribute to the disparity between our results
and previous studies of the LMNA and KLOTHO loci
including the low prior probability of any observed asso-
ciation, population stratification, and varying degrees of
linkage disequilibrium with neighbouring genes [20,25].
One of the most difficult potential confounders is under-
lying etiologic heterogeneity, magnified by the relatively
low resolution of many traditional clinical pheno-
types[24]. Clearly, not all CAD is caused by the same
mechanism, and there is variation in the biologic behav-
iour of the various syndromes, ranging from occult
chronic ischemia through to ischemic sudden death. The
heritable basis for each of these components in the "spec-
trum" of CAD may be quite distinct. This phenotypic het-
erogeneity remains an important issue despite our
rigorous use of coronary angiographic diagnoses. Our
control population was older and had a male predomi-
nance, both known cardiovascular risk factors. The patient
population had a higher prevalence of diabetes mellitus,
hypertension, and smoking. This is not unusual as most
patients with CAD already have documented cardiovascu-
lar risk factors [26], and it is conceivable that many 'risk
factors' are actually manifestations of subclinical forms of
vascular disease. By excluding patients presenting with
undifferentiated chronic stable CAD we hoped to mini-
mize the phenotypic heterogeneity. Nevertheless, it
remains possible that the progeroid genes we have studied
are associated with a particular subset of CAD, but not
with premature disease presenting as acute coronary syn-
dromes.
Additional factors also may explain our findings. Our
study would not have detected somatic mutations present
only in the vessel walls. While this is relatively unlikely
given the common progenitors shared by hematologic
and endothelial lineages, mutations restricted to more dif-
ferentiated cells may not be detectable. The association
between the KLOTHO gene and premature atherosclerosis
seen in the study by Arking, et al.[13] may reflect a chance
relationship between reduced survival from other causes
and a common trait, but by studying acute syndromes we
may have selected a distinct subset of disease in which the
effects of KLOTHO have been diluted.
Study limitations
Our study has several intrinsic limitations. The control
population did not undergo invasive clinical testing to
definitively exclude CAD, but nonetheless had extensive
non-invasive evaluations including echocardiography.
The genotype frequencies observed suggest that the cur-
rent study is adequately powered to detect a risk ratio of
1.8 or more [22], but would be unlikely to detect smaller
population wide effects or large effects from rare alleles.
The contributions of rare alleles would be better
addressed using a family based strategy[27].
Table 4: Genotype frequency of KLVS in cohort
Genotype PCAD* Frequency Controls Frequency Chi-square p-value
WW 216 73.5% 95 66.4% 2.321 0.13
WK 73 24.8% 44 30.8% 1.731 0.19
KK 5 1.7% 4 2.8% 0.574 0.45
Total 294 143
* PCAD: Group with premature coronary artery diseaseB
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Table 5: Analysis of SNPs in LMNA. Details of primers and probes used in TaqMan® analysis and PCR conditions for direct sequencing.
SNPs typed by TaqMan®
SNP ID Position Forward Primer (5'-3') Reverse Primer (5'-3') TaqMan® probe (VIC) TaqMan® probe (FAM)
rs955383 2,533 GGCCAGGAGTTTTAGACCAAATT TGAGTAGCTGAGACTATAGGCTATCATG ATAGCAAGgCTCCGTC TAGCAAGaCTCCGTCTC
rs2485662 3,971 ACTACCTTCTTTCTGGCTGAAACCAG GGGGAAGCAGGGCTGGG AGACCCAAtATTGGCT ACCCAAcATTGGCT
rs517606 9,827 CGAACTCCTAGGCTCAAGTAATCC GGGCTACAGACTAGAAAGAGACAGAGA CTGGGATgTATAGGCA CTGGGATtTATAGGCATGA
rs593987 16,890 TTGCTGTGCTGGTGCCTTT GAGTTGGCACTTGCAAATGTGA AGCCgGACTTCCT AGCCaGACTTCCTTG
rs528636 19,123 TCTAAATTCTGAGAGCCTCCTAGTACA GCAACTTAGATTCCGAGCTCCTT AGCAGCCaTTAGC AGCAGCCgTTAGC'
rs508641 20,642 GGAGAGAGAGGGAAAAGCATTCA TGACTCAGGGCTCAGGAACGT ACGGGGtAGAGCT ACGGGGcAGAGCT
rs553016 27,366 GCTTGGGACTCTGGGGAG CTTCCACACCAGGTCGGTA TCCCATCgCCACCCA TCCCATCaCCACCCA
rs4641 28,037 CGAGGATGAGGATGGAGATGA TCAGCGGCGGCTACCA TCCATCACCACCAcGTG CCATCACCACCAtGTG
rs7339 29,479 CAGAACTGCAGCATCATGTAATCTG GGGTTATTTTTCTTTGGCTTCAAG CCTGCACgTCATGG CCTGCACcTCATGG
rs3204564 30,139 AGGTGGAAGAAGGGAGAAGAAAG GCACCCCACTTGGCTTCA CCTAGCTTTAgACCCTGG CCTAGCTTTAaACCCTGG
rs536857 31,790 CACTGTGGGCTGGGGAACAC CCTCAGCCCTCCTCCTCAAGAG AGCAGGCaACGTT AGCAGGCgACGTT
SNPs typed by direct sequencing
SNP ID Position Primers(5'-3') PCR conditions
rs568036 30,669 These SNPs are contained in the amplicon 
amplified by the primers 5'-
ACTGCATCCTCCTGCTCATT-3' and 5'-
GGCTCCTACTTGGCCTAACA-3'
95°C for 2 min, followed by 35 cycles of 94°C 
for 30 s,60°C for 30 s, and 72°C for 90 s, 
followed by a 20 min 72°C final extension.
rs568035 30,670
rs6669212 30,816BMC Medical Genetics 2005, 6:38 http://www.biomedcentral.com/1471-2350/6/38
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Future genetic studies in CAD
Association studies remain controversial and our current
study demonstrates some of the problems encountered
with this approach. Despite rigorous phenotyping,
detailed haplotyping and adequate power to detect a
genetic effect of similar magnitude to that seen in previous
studies of CAD, we did not see any significant differences
in genetic architecture between our study and control
populations. We have therefore demonstrated that genes
associated with the progeroid syndrome are not likely to
have a major effect on the development of premature
atherosclerosis, despite a clear biological rationale.
In spite of the heterogeneity of CAD, insights from rare
Mendelian variants have proven broadly applicable. The
identification of new pathways through such familial
forms of CAD will contribute to our understanding of all
forms of vascular disease[2,3]. Linkage based family anal-
yses are likely to yield more robust results than association
studies and we believe increasingly will be used in future
studies on the genetics of CAD. Some disorders undoubt-
edly result from more common ancient alleles, and under-
standing the basic haplotype structure of the human
genome will facilitate their identification[28]. However,
the genetic dissection of common conditions will require
much more finely textured phenotypes than those tradi-
tionally employed in clinical medicine[24].
Conclusion
Common variants in aging syndrome genes previously
implicated in CAD are not associated with rigorously
defined premature acute CAD. This negative finding may
reflect the specific phenotypes tested and highlights one
of the major limitations of genetic association studies, the
phenotypic heterogeneity of most 'common' diseases.
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